Figure 1.

Amyloid removal by time. Graphs showing amyloid removal by time in clinical trial updated and redrawn from Karren and De Strooper⁴ and including data from van Dyck et al.¹ and data presented on gantenerumab presented at CTAD. The donenemab data are from phase 2 trials. The other data are from phase 3 trials. The aducanemab 2 trial is the one in which clinical benefit was reported: the aducaneman 1 trial is the one in which clinical benefit was not reported. Clinical benefit seems to become apparent at about the 40 centiloid level.